dengue quadrivalent vaccine rDENVΔ30 [live, attenuated] (V181) / Merck (MSD) - LARVOL DELTA

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002) (clinicaltrials.gov) - P2 | N=1364 | Completed | Sponsor: Butantan Institute | Active, not recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Dec 2024

Trial completion • Trial completion date • Dengue Fever

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002) (clinicaltrials.gov) - P2 | N=1364 | Active, not recruiting | Sponsor: Butantan Institute | Trial completion date: Nov 2024 ➔ Jun 2025

Trial completion date • Dengue Fever

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003) (clinicaltrials.gov) - P2 | N=1271 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion • Dengue Fever

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002) (clinicaltrials.gov) - P2 | N=1364 | Active, not recruiting | Sponsor: Butantan Institute | Recruiting ➔ Active, not recruiting

Enrollment closed • Dengue Fever

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002) (clinicaltrials.gov) - P2 | N=1240 | Recruiting | Sponsor: Butantan Institute | Active, not recruiting ➔ Recruiting | Trial completion date: Aug 2024 ➔ Dec 2024 | Trial primary completion date: Oct 2023 ➔ Jan 2024

Enrollment open • Trial completion date • Trial primary completion date • Dengue Fever

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002) (clinicaltrials.gov) - P2 | N=1240 | Active, not recruiting | Sponsor: Butantan Institute | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Aug 2024 | Trial primary completion date: Jan 2024 ➔ Oct 2023

Enrollment closed • Trial completion date • Trial primary completion date • Dengue Fever

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003) (clinicaltrials.gov) - P2 | N=1265 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Dengue Fever

"tautia kertaalleen ja saivat viruksen vasta 🦠 rokotuksen jälkeen. Suomalaisilla testataan #Phase2 ’kaikille_sopivaa’ #V181 rokotetta. Tutkimuskoodi: V181-003 EudraCT: 2020-004501-30 Yhtiö: @Merck (Jos sopisi kaikille, sitä ei tarvitsisi testata.) https://t.co/5U6eSIRnvl" (@riikka_kevoFIN)

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002) (clinicaltrials.gov) - P2 | N=1240 | Recruiting | Sponsor: Butantan Institute | Not yet recruiting ➔ Recruiting

Enrollment open • Dengue Fever

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002) (clinicaltrials.gov) - P2 | N=1240 | Not yet recruiting | Sponsor: Butantan Institute

New P2 trial • Dengue Fever

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003) (clinicaltrials.gov) - P2 | N=1265 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Dengue Fever

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003) (clinicaltrials.gov) - P2 | N=1265 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P2 trial • Dengue Fever